| Literature DB >> 25756039 |
Sylvie Tordjman1, Katherine S Davlantis2, Nicolas Georgieff3, Marie-Maude Geoffray3, Mario Speranza4, George M Anderson5, Jean Xavier6, Michel Botbol7, Cécile Oriol8, Eric Bellissant9, Julie Vernay-Leconte10, Claire Fougerou9, Anne Hespel9, Aude Tavenard9, David Cohen6, Solenn Kermarrec1, Nathalie Coulon11, Olivier Bonnot11, Geraldine Dawson2.
Abstract
There is a growing interest in the role of biological and behavioral rhythms in typical and atypical development. Recent studies in cognitive and developmental psychology have highlighted the importance of rhythmicity and synchrony of motor, emotional, and interpersonal rhythms in early development of social communication. The synchronization of rhythms allows tuning and adaptation to the external environment. The role of melatonin in the ontogenetic establishment of circadian rhythms and the synchronization of the circadian clocks network suggests that this hormone might be also involved in the synchrony of motor, emotional, and interpersonal rhythms. Autism provides a challenging model of physiological and behavioral rhythm disturbances and their possible effects on the development of social communication impairments and repetitive behaviors and interests. This article situates autism as a disorder of biological and behavioral rhythms and reviews the recent literature on the role of rhythmicity and synchrony of rhythms in child development. Finally, the hypothesis is developed that an integrated approach focusing on biological, motor, emotional, and interpersonal rhythms may open interesting therapeutic perspectives for children with autism. More specifically, promising avenues are discussed for potential therapeutic benefits in autism spectrum disorder of melatonin combined with developmental behavioral interventions that emphasize synchrony, such as the Early Start Denver Model.Entities:
Keywords: Early Start Denver Model; autism spectrum disorder; biological rhythms; emotional and relational rhythms; melatonin; motor; synchronization of rhythms; therapeutics
Year: 2015 PMID: 25756039 PMCID: PMC4337381 DOI: 10.3389/fped.2015.00001
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Studies of melatonin levels in individuals with autism.
| Study | Sample | Study group | Measured variable | Results |
|---|---|---|---|---|
| Ritvo et al. ( | Urine | Young adults with autism ( | Melatonin concentration | Increased daytime values compared to typically developing controls |
| Similar nighttime values compared to typically developing controls | ||||
| Nir et al. ( | Serum | Young men with autism ( | Melatonin concentration | Increased daytime values compared to typically developing controls |
| Decreased nighttime values compared to typically developing controls | ||||
| Kulman et al. ( | Serum | Children with autism ( | Melatonin concentration (24-h circadian rhythm) | Decreased nighttime values compared to typically developing controls |
| No circadian variation in 10/14 (71.4%) children with autism | ||||
| Inverted rhythm in 4/14 (28.6%) children with autism | ||||
| Tordjman et al. ( | Urine | Children and adolescents with autism ( | 6-Sulphatoxymelatonin excretion rate (12-h collection) | Decreased nighttime values compared to typically developing controls |
| Melke et al. ( | Plasma | Adolescents and young adults with autism ( | Melatonin concentration | Decreased daytime values compared to typically developing controls |
| Mulder et al. ( | Urine | Children and adolescents with autism ( | 6-Sulphatoxymelatonin excretion rate (24-h collection) | Trend to lower 24-h melatonin excretion rate in hyperserotonemic compared to normoserotonemic individuals with autism |
| Tordjman et al. ( | Urine | Post-pubertal adolescents and young adults with autism ( | 6-Sulphatoxymelatonin excretion rate (split 24-h collection) | Decreased daytime values compared to typically developing controls |
| Decreased nighttime values compared to typically developing controls | ||||
| No circadian variation in 10/43 (23.2%) individuals with autism |
Studies on potential therapeutic benefits of melatonin in autism.
| Study | Journal | Population | Design | Duration of treatment | Melatonin (formulation, dose) | Time of intake | Main outcome measures | Effects on sleep | Other outcomes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| Horrigan and Barnhill ( | 17-year-old boy with Asperger’s Syndrome (AS) | – | Not given | 3 mg | 20–30 min before bedtime (BB) | Sleep | Sleep improvement. No side effects | Daytime behavior improvement | – | |
| Hayashi ( | 14-year-old boy with autistic disorder, severe intellectual disability and phase delay with polyphasic sleep | – | 4 months | Immediate release (IR) 6 mg | 11:00 p.m. | Sleep | Melatonin increased sleep duration. No side effects | None | – | |
| Jan et al. ( | 12-year-old boy with AS and complex sleep disturbance (phase delay and parasomnias) | – | 6 months | Controlled release (CR) 5 mg | 30 min BB | Sleep | Normalization of the sleep–wake rhythm and disappearance of parasomnias. No side effects | None | – | |
| Gupta and Hutchins ( | 9 cases of children with autistic disorder (AD) aged from 2 to 11 years. Chronic sleep problems | Not given | 1 week to 1 year | IR 2.5–5 mg | 45 min BB | Parental evaluation of sleep | 56% showed improvement in total sleep duration | None | No standardized collection of sleep variables | |
| Andersen et al. ( | 107 children and adolescents aged from 2 to 18 years with ASD (DSM-IV): 71% AD, 5% AS, 19% PDDNOS (pervasive developmental disorder not otherwise specified) | Not given | Mean duration: 1.8 years | IR in 91% of the cases. Dose escalation protocol from 1 to 6 mg based upon age | 30–60 min BB | Parental evaluation of sleep | Parents reported full (25%) or partial (60%) improvement. Beneficial effects of melatonin seem to stop after 3–12 months despite the use of higher doses. Side effects observed in 3 children: sleepiness, fogginess, increased enuresis | None | No standardized collection of sleep variables. The loss of response to melatonin treatment is discussed in the text | |
| Galli-Carminatti et al. ( | 6 adult patients with AD (CIM-10) and intellectual disability, aged from 19 to 52 years | Not given | 6 months | IR. Dose escalation protocol from 3 to 9 mg if clinically required | 45 min BB | Sleep (CGI-S and CGI-I) | Improvement in sleep onset latency, night and early morning awakenings. No side effects | None | No standardized collection of sleep variables. Two to four associated psychotropic drugs per patient | |
| Jan et al. ( | 15 children with multiple neurological disabilities and severe sleep disorders | Not given | Not given | 2–10 mg | Bedtime | Not given | Partial improvement in sleep disorders. No side effects | Behavior and social improvement | Heterogeneous sleep disorders and neurological disabilities | |
| Ishizaki et al. ( | 50 children and young adults with autism ( | Not given | Not given | Not given | Not given | Sleep disorders and emotional/behavior disturbances | 34 patients experienced improvement in response to melatonin. Side effects reported in 17 patients | Improvements in excitability when sleep also improved. No change in contrariness, stereotyped behavior and in school/workshop refusal | Various types of insomnia and diagnoses | |
| Paavonen et al. ( | 15 children with AS (DSM-IV) aged from 6 to 17 years with severe sleep problems for at least 3 months | Not given | 14 days | IR 3 mg | 30 min BB | Sleep (72 h-period actigraphy, sleep diaries), daytime behavior (Karolina Sleepiness Scale; KSS), Child Behavior Checklist (CBCL) | Melatonin treatment was associated with significant decrease in sleep onset latency and nocturnal activity. Discontinuation of melatonin led to a significant decrease in sleep duration and more nocturnal activity. Side effects in 20% of the cases: tiredness, headaches, severe sleepiness, dizziness, diarrhea | Significant improvement of daytime behavior (CBCL) | No principal outcome specified. KSS is not validated in children nor in ASD | |
| Giannotti et al. ( | 29 children with AD (DSM-IV) aged from 2 to 9 years with current sleep problems | Controlled-release melatonin | 6 months | Dose escalation protocol from 3 mg (1 mg of IR + 2 mg of CR) to 6 mg when clinically required, based upon age (max 4 mg under 4 years old and max 6 mg over 6 years old) | 08:00 p.m. | Sleep (diaries and Children’s Sleep Habits Questionnaire CSHQ), daytime behavior, Childhood Autism Rating Scale (CARS) | Melatonin treatment was associated with improvement in sleep onset latency, night awakenings, and sleep duration, which vanished after melatonin discontinuation. No side effects | Parents reported less irritability, less anxiety, and better mood. Significant improvement of depression, anxiety, and withdrawal symptoms during melatonin treatment in children with AS. No effect was reported on the CARS | No principal outcome specified. Missing data: analyses on 25 patients | |
| De Leersnyder et al. ( | 88 children with heterogeneous neurodevelopmental disorders (Smith-Magenis syndrome, mental retardation, encephalopathy, Angelman syndrome, Rett syndrome, Bourneville syndrome, blindness, and autism) aged from 5 to 20 years. Seven patients with autism, mean age 12 years old | 6 years of open-label follow up | 3 months | CR 2–4 mg (<40 kg) or 6 mg (>40 kg) based upon weight | 60 min BB | Parental evaluation of sleep and mood (self-constructed questionnaire) | According to parental reports, both sleep latency and sleep duration improved within 3 months such as night awakenings, sleep quality, and daytime napping. Eleven children experienced adverse events (daytime nap, difficulties in swallowing tablets) that the parents attributed to melatonin treatment | 12% of the parents reported improvements of mood in their children | Heterogeneous neurodevelopmental disorders. Results cannot apply to a population with autism spectrum disorders. No standardized collection of sleep and mood parameters. Mean dose for patients with autism: 5.7 mg | |
| Malow et al. ( | 24 children with ASD (DSM-IV, ADOS): AD, AS, and PDDNOS aged from 3 to 9 years. Sleep onset delay of 30 min or longer confirmed on actigraphy. Exclusion of neurodevelopmental disabilities such as fragile X, Down, and Rett syndromes | Before treatment families received structured sleep education and children underwent a treatment acclimatation phase in order to be sure the melatonin will be taken | 14 weeks | CR. Dose escalation protocol from 2 to 9 mg when clinically required | 30 min BB | Sleep (actigraphy, Children’s Sleep Habits Questionnaire; CSHQ, diaries), daytime behavior (Child Behavior Checklist; CBCL, Repetitive Behavior Scale-Revised), parental stress (Parenting Stress Index Short Form), side effects (Hague Side Effects Scale) | Significant improvement in sleep latency within the first week of treatment but not for other sleep parameters such as night awakenings and sleep quality | Significant improvement in children’s behavior (withdrawal, affective problems, attention-deficit hyperactivity, stereotyped, and compulsive behaviors). Significant improvement in parental stress | No placebo | |
| McArthur and Budden ( | 9 children and adolescents with Rett syndrome aged from 4 to 17 years. Mean age:10 years old | Randomized double-blind crossover trial | 2 periods of 4 weeks with a wash out period of 1 week | 2.5–7.5 mg based on weight | 60 min BB | Sleep (actigraphy, diaries) | Significant improvement in total sleep time. No side effects | None | – | |
| Garstang and Wallis ( | 11 children and adolescents with ASD aged from 5 to 15 years with chronic sleep disorders resistant to behavioral treatment | Randomized double-blind crossover trial | 2 periods of 4 weeks with a wash out period of 1 week | IR 5 mg | 60 min BB | Sleep (diary) | Melatonin and placebo were associated with significantly decreased sleep latency and nocturnal awakenings, increased total sleep time. No side effects | Several parents and class teachers commented that their children were easier to manage and less rigid in their behavior while taking melatonin | ASD criteria were not consensual. Only 7 children completed the trial. Investigators found that some of the placebo capsules were empty. Missing data | |
| Wasdell et al. ( | 51 children and adolescents with neurodevelopmental disabilities (16 patients with ASD) aged from 2 to 18 years. Sleep delay phase syndrome and impaired sleep maintenance with resistant to sleep hygiene intervention | Randomized double-blind crossover trial. Three weeks trial followed by a 3-month open-label study. Behavioral sleep treatment before inclusion | 2 periods of 10 days with a wash out period of 3–5 days | Dose escalation protocol based on unspecified conditions: from 5 mg (1 mg FR + 4 mg CR) to 15 mg | 20–30 min BB | Sleep (actigraphy, diaries, CGI-S, CGI-I), familial stress (family stress scale) | Significant improvement in total sleep duration and sleep latency as well as reduced stress levels in parents in the melatonin arm | Half of the patients with ASD had their dose increased during the open-label phase with no additional improvement in sleep latency or sleep duration, but caregivers reported less anxiety | Unspecified ASD criteria. Fifty patients completed the trial and 47 completed the open-label phase. Selection bias due to previous melatonin treatment (25% of the cases). At the end of the trial, 29 patients received a dose of 10 or 15 mg. Higher doses were necessary in patients with bilateral cerebral lesions | |
| Wirojanan et al. ( | 12 children and adolescents with unspecified sleep problems, aged from 2 to 15 years: 5 patients with AD (ADOS and ADI-R), 3 patients with fragile X syndrome with AD, 3 patients with AD and fragile X syndrome, and 1 patient with fragile X premutation | Randomized double-blind crossover trial | 2 periods of 2 weeks. No wash out period | IR 3 mg | 30 min BB | Sleep (actigraphy, diary) | Significant, but mild improvement in total sleep time (+21 min) and decrease in sleep latency (−28 min) | None | Missing data: only 12 patients completed the trial (order bias). No subgroup analysis in AD patients. No side effects | |
| Wright et al. ( | 22 children and adolescents aged from 3 to 16 years with ASD (ICD-10, ADOS, ADI-R): AD (70%), AS (10%), and AA (20%). No fragile X or Rett syndrome. Current sleeplessness (confirmed on a 1-month-diary) and resistant to behavioral treatment | Randomized double-blind crossover trial | 2 periods of 3 months separated by 1 month of washout | IR. Dose escalation protocol from 2 to 10 mg when clinically required | 30–40 min BB | Sleep (sleep difficulties questionnaire, diary), daytime behavior (Developmental Behavior Checklist), side effect questionnaire | Significant improvement in sleep latency (−47 min) and total sleep duration (+52 min) in the melatonin arm. No improvement in night awakenings. The side effect profile was not significantly different between the 2 groups | Improvement in children’s behavior in the melatonin arm that was significant for communication ( | Missing data. Analysis on 16 patients. No actigraphy. Mean melatonin dose: 7 mg | |
| Cortesi et al. ( | 160 children with ASD (DSM-IV, ADI-R, ADOS) aged from 4 to 10 years with sleep onset insomnia and impaired sleep maintenance | Randomized placebo-controlled. Randomization in 4 groups: (1) melatonin alone (2) melatonin+ cognitive behavioral therapy (CBT) (3) CBT alone (4) placebo | 12 weeks | CR 3 mg | 09:00 p.m. | Sleep (actigraphy, Children’s Sleep Habits Questionnaire, diaries) | 144 patients completed the trial and 134 were analyzed. Combination group showed greater significant improvements on sleep followed by the melatonin alone and the CBT alone compared to placebo group. No side effects | None | – | |
| Gringas et al. ( | 146 children aged from 3 to 15 years with neurodevelopmental disorders (60 patients with ASD) and severe sleep disorders that did not respond to standardized sleep advice | Double-blind randomized multicentre placebo-controlled phase III trial | 12 weeks | Immediate release melatonin (dose escalation protocol from 0.5 to 12 mg) or matching placebo | 45 min before bedtime | Total sleep time after 12 weeks (sleep diaries and actigraphy); sleep onset latency; child behavior (Aberrant Behavior Checklist); family functioning; adverse events | Melatonin increased total sleep time by 22.4 min (diaries) and 13.3 (actigraphy); reduced sleep onset latency by 37.5 min (diaries) and 45.3 (actigraphy). Children in the melatonin group woke up earlier than the children in the placebo group. Melatonin was most effective in children with longest sleep latency. Adverse events were similar between the 2 groups | Child behavior and family functioning outcomes showed some (but not significant) improvement and favored use of melatonin | The results are not specified by category of developmental disorder | |
Review, meta-analysis, and discussion of therapeutic uses of melatonin in autism.
| Jan and O’Donnel ( | Review based on100 individuals with chronic sleep disorders, aged from 3 months to 21 years. Half of these 100 patients presented visual impairment or blindness. Melatonin dose ranged from 2.5 to 10 mg. Higher doses were needed in patients with impaired sleep maintenance. Partial or total improvement in sleep parameters was found in 82% of the cases. No side effects | |
| Jan et al. ( | Systematic review of studies on melatonin in children. Twenty-four studies found, most of them were case reports or uncontrolled studies with small samples. Mean age: 10 years old. Associated diagnosis: blindness and neurodevelopmental disabilities, 1 single case of an adolescent with AS ( | |
| Phillips and Appleton ( | Only three studies, reporting a total of 35 children, fulfilled the criteria for inclusion (randomized controlled clinical trials). Two of them reported a significant decrease in time to sleep onset | |
| Braam et al. ( | Meta-analysis of placebo-controlled randomized trials of melatonin in individuals with intellectual disabilities and sleep problems. Nine studies were included. Various doses and formulations of melatonin were given. Melatonin decreased sleep latency by a mean of 34 min ( | |
| Guénolé et al. ( | Systematic review of efficacy and safety of exogenous melatonin for treating disordered sleep in individuals with autism spectrum disorders: 4 case reports, 3 retrospective studies, 2 open-label clinical trials, 3 placebo-controlled trials. All studies supported the existence of a beneficial effect of melatonin on sleep in individuals with ASD with minor side effects. Limitations are: small sample, clinical heterogeneity of ASD and sleep disorders, varying methods used to measure sleep, confounding factors such as behavioral interventions and cross over design (no analysis of intention to treat). Melatonin doses ranged from 0.75 to 10 mg/day. The authors propose that future research on the efficacy of melatonin in children with ASD should include daytime functioning as a principal outcome measure. Only 6 patients of 205 presented side effects: daytime sleepiness, fogginess, dizziness, nocturnal enuresis, tiredness, headache, and diarrhea | |
| Doyen et al. ( | Systematic review on pharmacokinetics data on melatonin and its role in sleep disorders and autism spectrum disorders. Authors reviewed 17 studies on effectiveness and side effects of melatonin in patients with AD, AS, PDDNOS, and Rett syndrome. Effectiveness on sleep disorders was found in all the studies, side effects were reported in 5 studies. Melatonin doses ranged from 0.5 to 10 mg. Melatonin seems to have anxiolytic properties. Most frequent reported side effects: infections, flu, epilepsy, intestinal disorders, and agitation | |
| Rossignol and Frye ( | Aim of the study: investigate melatonin-related findings in ASD including AD, AS, Rett syndrome, and PDDNOS. Eighteen studies on melatonin treatment on ASD patients were identified (5 RCT), 12 of them reported improvement in sleep with melatonin in 67% to 100% of the patients. Six studies reported improvement in daytime behavior (less behavioral rigidity, ease of management for parents and teachers, better social interaction, fewer temper tantrums, less irritability, more playfulness, better academic performance, and increased alertness). Melatonin doses ranged from 0.75 to 15 mg, age of patients ranged from 2 to 18 years, treatment duration ranged from 2 weeks to 4 years. Twelve studies explored side effects (headache, tiredness, dizziness, and diarrhea) in which 7 studies reported no side effects. Nine studies found low levels or abnormal circadian rhythm of melatonin in ASD. A correlation between these abnormal levels and autistic behaviors was found in 4 studies. Night time urinary excretion of melatonin metabolite (6-SM) was reported to be inversely correlated with the severity of impairments in verbal communication, play, and daytime sleepiness in patients with ASD. Five studies found genetic abnormalities of melatonin receptor and enzymes involved in melatonin synthesis | |
| Reading ( | Correlation between plasmatic levels of melatonin and autistic behaviors was found. Melatonin groups showed improvements in total sleep duration and sleep onset latency versus placebo groups but not on night awakenings | |
| Guénolé and Baleyte ( | Response to the Rossignol and Frye review ( | |
| Guénolé and Baleyte ( | Response to the De Leersnyder et al. study ( | |
| Jan and Freeman ( | Discussion on melatonin use in children with ADHD, ASD, neurodevelopmental disabilities, epilepsy, and blindness. Exogenous melatonin seems to regulate endogenous melatonin secretion. It seems to be more effective in sleep–wake cycle disorders with sleep onset delay disorders. Night and morning awakenings seem to be more difficult to treat, such as sleep problems associated with cerebral lesions. The more the child shows mental or motor comorbidities, the more the melatonin dose is high | |
| Lord ( | General brief discussion of melatonin and its potential for treating sleep problems in autism | |